{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:22:27Z","timestamp":1790738547227,"version":"4.1.0"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2017-0013_s_006_w2aab3b7c32b1b6b1aab1c15b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pseudomyxoma peritonei (PMP) is difficult to treat. Intraperitoneal delivery of mucolytic solutions might potentially improve therapy, in addition to surgical cytoreduction and hyperthermic intraperitoneal chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0013_s_007_w2aab3b7c32b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Comparison of mucolytic effect of two formulations (control: bromelain 300\u2006\u00b5g\/mL+N-Acetylcystein 250\u2006mM; test: bromelain 200\u2006\u00b5g\/mL+200\u2006mM cysteamine)\n                      <jats:italic>in vitro<\/jats:italic>\n                      on a mucin producing cell lines (HT29) and\n                      <jats:italic>ex vivo<\/jats:italic>\n                      on mucus obtained from 18 PMP patients. Mucin plugs were classified according to their density into three categories: hard, semi hard and soft. Simulation of peritoneal washing\n                      <jats:italic>ex vivo<\/jats:italic>\n                      using a closed heated circulating pump.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0013_s_008_w2aab3b7c32b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Solubilisation was faster with the test vs. the control formulation (90 vs. 180 min) for dissolving the soft mucin plugs (p\u2006&lt;\u20060.05). The test solution was also more effective in dissolving the hard mucus plugs compared to control (82.5\u00b12.74\u2006% vs. 36.33\u00b13.27\u2006%). All mucin types disintegrated in simulated peritoneal washing. Cytotoxicity of the test solution on HT29 cell line was time-dependent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0013_s_009_w2aab3b7c32b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The test formulation is more effective and faster than the control formulation in dissolving mucus plugs of various densities. Mucus plugs were all solubilised after 40 min in simulated peritoneal washing. This novel mucolytic formulation might pave the way for an effective and less invasive therapy of PMP in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2017-0013","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T06:03:23Z","timestamp":1497938603000},"page":"111-117","source":"Crossref","is-referenced-by-count":17,"title":["Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an\n                    <i>ex vivo<\/i>\n                    and\n                    <i>in vitro<\/i>\n                    study"],"prefix":"10.1515","volume":"2","author":[{"given":"Krishna","family":"Pillai","sequence":"first","affiliation":[{"name":"Department of Surgery , University of New South Wales , St. George Hospital , Kogarah , NSW 2217 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Akhter","sequence":"additional","affiliation":[{"name":"Department of Surgery , University of New South Wales , St. George Hospital , Kogarah , NSW 2217 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Surgery , University of New South Wales , St. George Hospital , Kogarah , NSW 2217 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2017,6,6]]},"reference":[{"key":"2025120909204648664_j_pp-2017-0013_ref_001_w2aab3b7c32b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Moran BJ, Cecil TD. The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 2003;12:585\u2013603.","DOI":"10.1016\/S1055-3207(03)00026-7"},{"key":"2025120909204648664_j_pp-2017-0013_ref_002_w2aab3b7c32b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994;219:112\u20139.","DOI":"10.1097\/00000658-199402000-00002"},{"key":"2025120909204648664_j_pp-2017-0013_ref_003_w2aab3b7c32b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surgical Oncol 2008;34:196\u2013201.","DOI":"10.1016\/j.ejso.2007.04.002"},{"key":"2025120909204648664_j_pp-2017-0013_ref_004_w2aab3b7c32b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Bevan KE, Mohamed F, Moran BJ. Pseudomyxoma peritonei. World J Gastrointest Oncol 2010;2:44\u201350.","DOI":"10.4251\/wjgo.v2.i1.44"},{"key":"2025120909204648664_j_pp-2017-0013_ref_005_w2aab3b7c32b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surgical Oncol 2001;27:239\u201343.","DOI":"10.1053\/ejso.2000.1038"},{"key":"2025120909204648664_j_pp-2017-0013_ref_006_w2aab3b7c32b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clinical Oncol 2012;30:2449\u201356.","DOI":"10.1200\/jco.2012.30.4_suppl.532"},{"key":"2025120909204648664_j_pp-2017-0013_ref_007_w2aab3b7c32b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum 2007;50:37\u201342.","DOI":"10.1007\/s10350-006-0741-9"},{"key":"2025120909204648664_j_pp-2017-0013_ref_008_w2aab3b7c32b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 2005;241:300\u20138.","DOI":"10.1097\/01.sla.0000152015.76731.1f"},{"key":"2025120909204648664_j_pp-2017-0013_ref_009_w2aab3b7c32b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Pillai K, Akhter J, Chua TC, Morris DL. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei. International journal of cancer 2014;134:478\u201386.","DOI":"10.1002\/ijc.28380"},{"key":"2025120909204648664_j_pp-2017-0013_ref_010_w2aab3b7c32b1b6b1ab2b1c10Aa","unstructured":"Akhter J, Pillai K, Chua TC, Alzarin N, Morris DL. Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters. Am J Cancer Res 2014;4:495\u2013507."},{"key":"2025120909204648664_j_pp-2017-0013_ref_011_w2aab3b7c32b1b6b1ab2b1c11Aa","unstructured":"Mantle M, Stewart G, Zayas G, King M. The disulphide-bond content and rheological properties of intestinal mucins from normal subjects and patients with cystic fibrosis. Biochem J 1990;266:597\u2013604."},{"key":"2025120909204648664_j_pp-2017-0013_ref_012_w2aab3b7c32b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Inagami T, Murachi T. Kinetic studies of bromelain catalysis. Biochemistry 1963;2:1439\u201344.","DOI":"10.1021\/bi00906a041"},{"key":"2025120909204648664_j_pp-2017-0013_ref_013_w2aab3b7c32b1b6b1ab2b1c13Aa","unstructured":"Rubin BK. Mucolytics, expectorants, and mucokinetic medications. Respir Care 2007;52:859\u201365."},{"key":"2025120909204648664_j_pp-2017-0013_ref_014_w2aab3b7c32b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med 2008;359:285\u201392.","DOI":"10.1056\/NEJMct0708278"},{"key":"2025120909204648664_j_pp-2017-0013_ref_015_w2aab3b7c32b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Lee SM, Jeong EM, Jeong J, Shin DM, Lee HJ, Kim HJ, et al. Cysteamine prevents the development of lens opacity in a rat model of selenite-induced cataract. Invest Ophthalmol Vis Sci 2012;53:1452\u20139.","DOI":"10.1167\/iovs.11-8636"},{"key":"2025120909204648664_j_pp-2017-0013_ref_016_w2aab3b7c32b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Fujisawa T, Rubin B, Suzuki A, Patel PS, Gahl WA, Joshi BH, et al. Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer. Plos One 2012;7:e34437.","DOI":"10.1371\/journal.pone.0034437"},{"key":"2025120909204648664_j_pp-2017-0013_ref_017_w2aab3b7c32b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Dickinson DA, Forman HJ. Glutathione in defense and signaling: lessons from a small thiol. Ann N Y Acad Sci 2002;973:488\u2013504.","DOI":"10.1111\/j.1749-6632.2002.tb04690.x"},{"key":"2025120909204648664_j_pp-2017-0013_ref_018_w2aab3b7c32b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Besouw M, van den Heuvel L, van Eijsden R, Bongaers I, Kluijtmans L, Dewerchin M, et al. Increased human dermal microvascular endothelial cell survival induced by cysteamine. J Inherit Metab Dis 2013;36:1073\u20137.","DOI":"10.1007\/s10545-013-9588-0"},{"key":"2025120909204648664_j_pp-2017-0013_ref_019_w2aab3b7c32b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 1999;31:273\u2013300.","DOI":"10.1080\/10715769900300851"},{"key":"2025120909204648664_j_pp-2017-0013_ref_020_w2aab3b7c32b1b6b1ab2b1c20Aa","unstructured":"Rowan AD, Buttle DJ, Barrett AJ. The cysteine proteinases of the pineapple plant. Biochem J 1990;266:869\u201375."},{"key":"2025120909204648664_j_pp-2017-0013_ref_021_w2aab3b7c32b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Hatano K, Sawano Y, Miyakawa T, Tanokura M. Characterization of the acidic and basic limbs of a bell-shaped pH profile in the inhibitory activity of bromelain inhibitor VI. Biopolymers 2006;81:309\u201319.","DOI":"10.1002\/bip.20419"},{"key":"2025120909204648664_j_pp-2017-0013_ref_022_w2aab3b7c32b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112\u20136.","DOI":"10.1038\/nprot.2006.179"},{"key":"2025120909204648664_j_pp-2017-0013_ref_023_w2aab3b7c32b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Macri A. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol 2010;2:68\u201375.","DOI":"10.4251\/wjgo.v2.i2.68"},{"key":"2025120909204648664_j_pp-2017-0013_ref_024_w2aab3b7c32b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Charrier C, Rodger C, Robertson J, Kowalczuk A, Shand N, Fraser-Pitt D, et al. Cysteamine (Lynovex(R)), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis. Orphanet J Rare Dis 2014;9:189.","DOI":"10.1186\/s13023-014-0189-2"},{"key":"2025120909204648664_j_pp-2017-0013_ref_025_w2aab3b7c32b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Chobotova K, Vernallis AB, Majid FA. Bromelain activity and potential as anti-cancer agent: current evidence and perspectives. Cancer Lett 2010;290:148\u201356.","DOI":"10.1016\/j.canlet.2009.08.001"},{"key":"2025120909204648664_j_pp-2017-0013_ref_026_w2aab3b7c32b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Castell JV, Fredrick G, Kuhn CS, Poppe GE. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol 1997;273:G139\u201346.","DOI":"10.1152\/ajpgi.1997.273.1.G139"},{"key":"2025120909204648664_j_pp-2017-0013_ref_027_w2aab3b7c32b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Amini A, Ehteda A, Masoumi Moghaddam S, Akhter J, Pillai K, Morris DL. Cytotoxic effects of bromelain in human gastrointestinal carcinoma cell lines (MKN45, KATO-III, HT29-5F12, and HT29-5M21). Onco Targets Ther 2013;6:403\u20139.","DOI":"10.2147\/OTT.S43072"},{"key":"2025120909204648664_j_pp-2017-0013_ref_028_w2aab3b7c32b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Pillai KJA, Etheda A, Badar S, Chua TC, David DL. Anti-tumor and chemosensitising effect of a combination of bromelain+N-acetyl cysteine with cisplatin or 5-FU on malignant peritoneal mesothelioma cells. J Glycobiology 2013:1\u201310.","DOI":"10.4172\/2168-958X.S1-005"},{"key":"2025120909204648664_j_pp-2017-0013_ref_029_w2aab3b7c32b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Pillai K, Ehteda A, Akhter J, Chua TC, Morris DL. Anticancer effect of bromelain with and without cisplatin or 5-FU on malignant peritoneal mesothelioma cells. Anti-Cancer Drugs 2014;25:150\u201360.","DOI":"10.1097\/CAD.0000000000000039"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/2\/2\/article-p111.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0013\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0013\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:44:27Z","timestamp":1765277067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0013\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6,6]]},"published-print":{"date-parts":[[2017,6,5]]}},"alternative-id":["10.1515\/pp-2017-0013"],"URL":"https:\/\/doi.org\/10.1515\/pp-2017-0013","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}